Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C P Larsen

Showing results (61-70 of 127) with videos related to

Pageof 13
Sort By:
Transplantation|April 15, 1996
CTLA4-Ig plus bone marrow induces long-term allograft survival and donor specific unresponsiveness in the murine model. Evidence for hematopoietic chimerismT C Pearson, D Z Alexander, R Hendrix, et al.
Transplantation|September 27, 1995
Delayed urinary bladder leak after combined kidney-pancreas transplantation. Association with penile prosthesis implantationT C Pearson, A A Futral, K L Routenberg, et al.
Clinical Transplantation|June 1, 1997
Drainage of the exocrine pancreas in clinical transplantation: comparison of bladder versus enteric drainage in a consecutive seriesT C Pearson, P J Santamaria, K L Routenberg, et al.
Transplantation|May 27, 1997
Analysis of the B7 costimulatory pathway in allograft rejectionT C Pearson, D Z Alexander, M Corbascio, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|May 15, 2017
Increased Pretransplant Frequency of CD28<sup>+</sup> CD4<sup>+</sup> T<sub>EM</sub> Predicts Belatacept-Resistant Rejection in Human Renal Transplant RecipientsM Cortes-Cerisuelo, S J Laurie, D V Mathews, et al.
Transplantation|January 15, 1996
CD40-gp39 interactions play a critical role during allograft rejection. Suppression of allograft rejection by blockade of the CD40-gp39 pathwayC P Larsen, D Z Alexander, D Hollenbaugh, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|August 1, 2017
Ten-year outcomes in a randomized phase II study of kidney transplant recipients administered belatacept 4-weekly or 8-weeklyF Vincenti, G Blancho, A Durrbach, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|March 7, 2018
De novo donor-specific antibodies in belatacept-treated vs cyclosporine-treated kidney-transplant recipients: Post hoc analyses of the randomized phase III BENEFIT and BENEFIT-EXT studiesR A Bray, H M Gebel, R Townsend, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|March 25, 2018
Posttransplant reduction in preexisting donor-specific antibody levels after belatacept- versus cyclosporine-based immunosuppression: Post hoc analyses of BENEFIT and BENEFIT-EXTR A Bray, H M Gebel, R Townsend, et al.
Transplantation|August 5, 2000
Analysis of expression and function of the costimulatory molecule 4-1BB in alloimmune responsesJ T Tan, J Ha, H R Cho, et al.
Pageof 13

Showing results (61-70 of 127) with videos related to

Sort By:
Pageof 13
Transplantation|April 15, 1996
CTLA4-Ig plus bone marrow induces long-term allograft survival and donor specific unresponsiveness in the murine model. Evidence for hematopoietic chimerismT C Pearson, D Z Alexander, R Hendrix, et al.
Transplantation|September 27, 1995
Delayed urinary bladder leak after combined kidney-pancreas transplantation. Association with penile prosthesis implantationT C Pearson, A A Futral, K L Routenberg, et al.
Clinical Transplantation|June 1, 1997
Drainage of the exocrine pancreas in clinical transplantation: comparison of bladder versus enteric drainage in a consecutive seriesT C Pearson, P J Santamaria, K L Routenberg, et al.
Transplantation|May 27, 1997
Analysis of the B7 costimulatory pathway in allograft rejectionT C Pearson, D Z Alexander, M Corbascio, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|May 15, 2017
Increased Pretransplant Frequency of CD28<sup>+</sup> CD4<sup>+</sup> T<sub>EM</sub> Predicts Belatacept-Resistant Rejection in Human Renal Transplant RecipientsM Cortes-Cerisuelo, S J Laurie, D V Mathews, et al.
Transplantation|January 15, 1996
CD40-gp39 interactions play a critical role during allograft rejection. Suppression of allograft rejection by blockade of the CD40-gp39 pathwayC P Larsen, D Z Alexander, D Hollenbaugh, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|August 1, 2017
Ten-year outcomes in a randomized phase II study of kidney transplant recipients administered belatacept 4-weekly or 8-weeklyF Vincenti, G Blancho, A Durrbach, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|March 7, 2018
De novo donor-specific antibodies in belatacept-treated vs cyclosporine-treated kidney-transplant recipients: Post hoc analyses of the randomized phase III BENEFIT and BENEFIT-EXT studiesR A Bray, H M Gebel, R Townsend, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|March 25, 2018
Posttransplant reduction in preexisting donor-specific antibody levels after belatacept- versus cyclosporine-based immunosuppression: Post hoc analyses of BENEFIT and BENEFIT-EXTR A Bray, H M Gebel, R Townsend, et al.
Transplantation|August 5, 2000
Analysis of expression and function of the costimulatory molecule 4-1BB in alloimmune responsesJ T Tan, J Ha, H R Cho, et al.
Pageof 13